The EIF2AK2 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian clear cell carcinoma line, featuring targeted disruption of the EIF2AK2 gene. This heterogeneous pool of genetically modified cells enables loss-of-function analysis of protein kinase R (PKR) without the selective bottlenecks of clonal isolation, thus preserving broader cellular diversity and providing a robust model for studying PKR-dependent signaling in a physiologically relevant epithelial ovarian cancer background. The polyclonal format is particularly suited for functional genomics, drug sensitivity screens, and assays requiring population-level responses to stimuli such as double-stranded RNA (dsRNA) or interferons.
The host MES-OV cell line is an established model of ovarian clear cell carcinoma, an aggressive epithelial ovarian cancer subtype characterized by intrinsic chemoresistance and distinct molecular features. Originating from human tumor tissue, MES-OV cells retain key characteristics of clear cell carcinoma, including activation of stress-responsive and innate immune pathways. This genetic background offers a clinically pertinent context for investigating how PKR functions intersect with ovarian cancer biology, particularly in the regulation of antiviral defenses, inflammatory signaling, and apoptotic thresholds that influence therapeutic outcomes.
EIF2AK2 encodes PKR, a serine/threonine kinase that serves as a critical sensor of viral dsRNA. Upon binding dsRNA or interacting with activators such as PACT/PRKRA, PKR undergoes dimerization and autophosphorylation, subsequently phosphorylating the alpha subunit of eukaryotic initiation factor 2 (eIF2??) at Ser51. This event triggers global translational arrest while selectively enhancing translation of stress-responsive transcription factors like ATF4. Beyond translational control, PKR activates the IKK complex, leading to NF-??B nuclear translocation and expression of pro-inflammatory cytokines, and also stimulates p38 MAPK and JNK pathways that contribute to stress-induced apoptosis via caspase-8. Interactions with TRBP (TARBP2), TAR RNA, and the inhibitor p58IPK further modulate PKR activity, delineating a multifaceted signaling hub.
In the context of ovarian clear cell carcinoma, PKR-mediated signaling is implicated in tumor cell-autonomous immune surveillance, regulation of stress granule dynamics, and modulation of chemosensitivity. Disruption of EIF2AK2 in MES-OV cells permits dissection of how PKR influences dsRNA-triggered inflammatory responses and translational reprogramming, processes that may determine the balance between cell survival and apoptosis during oncogenic stress or therapy. The polyclonal knockout population enables researchers to assess these mechanisms without confounding clonal adaptations, yielding data that more faithfully represent the heterogeneous tumor microenvironment.
This product is ideal for investigations into PKR-mediated antiviral defenses, interferon signaling, translational regulation, and innate immune signaling in ovarian cancer. Experimental approaches include Western blotting for phospho-eIF2?? (Ser51) and downstream effectors, RT-qPCR profiling of interferon-stimulated genes, RNA-seq analysis following dsRNA stimulation to map transcriptome-wide changes, immunofluorescence detection of stress granules, flow cytometry-based apoptosis assays, and drug sensitivity testing with chemotherapeutic agents. Co-immunoprecipitation studies can further probe PKR interactions with dsRNA, PACT, or eIF2??. For further information, please contact Ascent Research.
